Rachel D. Totoritis

发表

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

Michelle C. Schaeffer, Carol A. Capriotti, P. A. Harris, 2017, Journal of medicinal chemistry.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Philip Hardwicke, John Bertin, Bryan W King, 2015, Bioorganic & medicinal chemistry.

A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.

Ramona N Plant, K. Brown, J. Briand, 2014, Nature chemical biology.

Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery

Beth L. Pietrak, Marc A. Holbert, Yong Jiang, 2019, Scientific Reports.

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Michelle C. Schaeffer, Carol A. Capriotti, Paul E. Lamoureux, 2019, Journal of medicinal chemistry.

Characterization of Apo‐Form Selective Inhibition of Indoleamine 2,3‐Dioxygenase **

Douglas W. Thomson, Rodrigo F. Ortiz-Meoz, G. Bergamini, 2020, Chembiochem : a European journal of chemical biology.

Characterization of apo-form selective inhibition of indoleamine 2,3-dioxygenase

Douglas W. Thomson, Rodrigo F. Ortiz-Meoz, G. Bergamini, 2020, bioRxiv.

Characterization of novel inhibition of indoleamine 2,3-dioxygenase by targeting its apo form.

Douglas W. Thomson, Rodrigo F. Ortiz-Meoz, G. Bergamini, 2018 .

Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).

D. Holt, A. P. Graves, L. Shewchuk, 2015, Journal of medicinal chemistry.

Identi fi cation of Purines and 7 ‐ Deazapurines as Potent and Selective Type I Inhibitors of Troponin I ‐ Interacting Kinase ( TNNI 3 K )

D. Holt, A. P. Graves, L. Shewchuk, 2015 .

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis.

Michelle C. Schaeffer, Carol A. Capriotti, P. A. Harris, 2013, ACS medicinal chemistry letters.

DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.

Deepak Bandyopadhyay, Lauren Dare, Michelle C. Schaeffer, 2016, Journal of medicinal chemistry.

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Carol A. Capriotti, J. Bertin, M. Convery, 2016, Journal of medicinal chemistry.

Evaluation of an antibody-free ADP detection assay: ADP-Glo.

Peter Caprioli, Guofeng Zhang, Rachel D. Totoritis, 2009, Assay and drug development technologies.

Understanding the origins of time-dependent inhibition by polypeptide deformylase inhibitors.

S. Thrall, C. Duraiswami, T. Meek, 2011, Biochemistry.

Modular Protein Ligation: A New Paradigm as a Reagent Platform for Pre-Clinical Drug Discovery

Marc A. Holbert, Yong Jiang, L. Szewczuk, 2019, Scientific Reports.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

J. Bertin, M. Convery, D. Lipshutz, 2018, ACS medicinal chemistry letters.

Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity

Leanna E. Shuster, K. Evans, S. Sweitzer, 2015, Molecular Pharmacology.

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer

P. A. Harris, J. Bertin, M. Mahajan, 2019, ACS medicinal chemistry letters.

Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38α, and B-Raf.

D. Holt, A. P. Graves, L. Shewchuk, 2021, Journal of medicinal chemistry.

Long-Range Inhibitor-Induced Conformational Regulation of Human IRE1α Endoribonuclease Activity

Leanna E. Shuster, K. Evans, C. Buser, 2015, Molecular Pharmacology.

A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.

Ramona N Plant, K. Brown, J. Briand, 2014, Nature chemical biology.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Carol A. Capriotti, J. Bertin, M. Convery, 2018, ACS medicinal chemistry letters.